Switch to:
More From Other Websites
2:23 am Regeneron Pharms and Sanofi (SNY) announce Praluent... Jan 27 2015
Regeneron vaults ahead of Amgen in race to market cholesterol drug Jan 26 2015
Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race Jan 26 2015
Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been... Jan 26 2015
Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been... Jan 26 2015
Regeneron/Sanofi cholesterol drug gets FDA priority review Jan 26 2015
Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race Jan 26 2015
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due... Jan 23 2015
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due... Jan 23 2015
Ebola vaccine trials to begin in Liberia Jan 22 2015
US investors double down on biotech bets Jan 22 2015
Cramer's Stop Trading: Biotech hangover Jan 20 2015
Regeneron CEO: Choice, not price best for patients Jan 20 2015
New York drug developer's big money maker had nearly $1.74B in sales last year Jan 14 2015
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 13 2015
Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been... Jan 12 2015
Sanofi, Regeneron submit new cholesterol drug to EMA for review Jan 12 2015
Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been... Jan 12 2015
A volatile end to a very volatile week... Jan 09 2015
Regeneron Jumps On Favorable Cholesterol Drug Report Jan 09 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK